{"classes":[{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation could not be estimated as none of the observations were above the lower limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Encorafenib: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"212","value":"10.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Encorafenib: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"417","value":"11.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Encorafenib: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"141","value":"9.336"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Encorafenib: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"111","value":"9.175"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Encorafenib: Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"466","value":"13.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Encorafenib: Cycle 6 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric mean and geometric coefficient of variation could not be estimated as none of the observations were above the lower limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"LHY746: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"258","value":"40.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"LHY746: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"250","value":"33.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"LHY746: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"153","value":"25.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"LHY746: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"210","value":"29.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"LHY746: Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"271","value":"43.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"LHY746: Cycle 6 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Trough plasma concentration of encorafenib and its metabolite LHY746 was measured in this outcome measure.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Cohort 3: Arm D [EC + FOLFIRI]"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK concentration set was defined as all enrolled participants who were treated and had at least 1 analyte concentration. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Here, \"Number Analyzed\" signifies participants evaluable at specified timepoints. As pre-specified in the protocol of the study, this outcome measure was planned only for Arm D of Cohort 3. Hence, data is not reported for Arm E.","reportingStatus":"POSTED","timeFrame":"Predose on Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1 and Cycle 6 Day 1","title":"Cohort 3: Trough Plasma Concentration of Encorafenib and Its Metabolite LHY746","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}